Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Rhea-AI Summary

Xencor (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, has announced a Research & Development Webcast and Conference Call scheduled for Monday, September 9, 2024, at 8:00 a.m. ET. The event will introduce new XmAb® programs for treating autoimmune diseases and provide updates on oncology programs, including:

• XmAb819 (ENPP3 x CD3) for advanced clear cell renal cell carcinoma
• XmAb808 (B7-H3 x CD28) for advanced solid tumors

The webcast can be accessed through the Investors section of Xencor's website. A recording will be available for at least 30 days after the event.

PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will host a webcast and conference call at 8:00 a.m. ET (5:00 a.m. PT) on Monday, September 9, 2024 to introduce new XmAb® programs in development for the treatment of patients with autoimmune diseases and to provide updates on continued progress in dose escalation with first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and XmAb808 (B7-H3 x CD28) in patients with advanced solid tumors.

The live webcast may be accessed through “Events & Presentations” in the Investors section of the Company’s website, located at investors.xencor.com. Telephone participants may register to receive a dial-in number and unique passcode that can be used to access the conference call. A recording will be available for at least 30 days.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a proteins structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240906599943/en/

Charles Liles

cliles@xencor.com

(626) 737-8118

Source: Xencor, Inc.

FAQ

When is Xencor's Research & Development Webcast and Conference Call scheduled for 2024?

Xencor's Research & Development Webcast and Conference Call is scheduled for Monday, September 9, 2024, at 8:00 a.m. ET (5:00 a.m. PT).

What new programs will Xencor introduce during the September 2024 webcast?

Xencor will introduce new XmAb® programs in development for the treatment of patients with autoimmune diseases during the September 2024 webcast.

Which oncology programs will Xencor provide updates on during the September 2024 event?

Xencor will provide updates on XmAb819 (ENPP3 x CD3) for advanced clear cell renal cell carcinoma and XmAb808 (B7-H3 x CD28) for advanced solid tumors.

How can investors access Xencor's September 2024 Research & Development Webcast?

Investors can access the live webcast through the 'Events & Presentations' section in the Investors area of Xencor's website at investors.xencor.com.

What is Xencor's stock symbol?

Xencor's stock symbol is XNCR, and it is traded on the NASDAQ stock exchange.